Biolase Diode Laser Now Available SACRAMENTO, CA, UNITED STATES, March 5, 2026 /EINPresswire.com/ -- OEM GPS Navigation ...
ESA’s Jupiter Icy Moons Explorer (JUICE) that was launched in 2023 will take about 8 years to arrive at the jovian system after several gravity assists. Credit: Space.com | animation courtesy: ESA / ...
Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...
Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...
Proteinuria affects most people with complement 3 glomerulopathy (C3G). Protein in urine is one of the strongest indicators of disease progression. Reducing proteinuria can slow the progression of C3G ...
Complement 3 glomerulopathy (C3G) is diagnosed with a combination of a clinical evaluation, blood tests, urine tests, and a renal (kidney) biopsy. The only way to definitively diagnose C3G and its ...
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration CTx001 is an investigational AAV-based gene therapy designed to modulate ...
In 2019 I wrote about research suggesting anti-inflammatory medications might help some people with major depression. At the time, the idea that depression could have roots in the immune system felt ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
After announcing the Android 16-based OxygenOS 16, OnePlus has begun rolling out this new operating system globally. The OnePlus 12R is the latest device to receive this update. The update is ...
The OnePlus Open is now receiving the Android 16-based OxygenOS 16 update, following the rollout for the OnePlus 12 and 13R. The global model is included, with the update starting in India before ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results